Skip to content

PeptideKnow Peptide News, Safety, Dosages & Research

Home
Peptides

Browse by Category
All Categories →

Weight Loss & Metabolic 35 peptides Healing & Recovery 34 peptides Anti-Aging & Longevity 28 peptides Neuroprotective 22 peptides Cognitive & Nootropic 18 peptides Muscle Growth 16 peptides Pain & Inflammation 16 peptides Immune Support 14 peptides Related Compounds 10 peptides Growth Hormone Secretagogues 9 peptides Sexual Health 7 peptides Skin & Hair 7 peptides Mitochondrial 6 peptides Antimicrobial 6 peptides Sleep 5 peptides SARMs & Androgen Modulators 3 peptides

View All Peptides Search Database
Guides
Beginner's Guide Stacking Guide Routes of Administration Reconstitution Guide How Peptides Are Made Peptides vs SARMs
Calculator
News

Latest Articles
45 articles

Regulation FDA PCAC July 2026: What the BPC-157 peptide compounding review really means FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. Wh... Jun 2, 2026 · 9 min read

Regulation FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack... Jun 1, 2026 · 8 min read

Regulatory Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the ... May 30, 2026 · 10 min read

weight-loss-metabolic Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3 Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regress... May 29, 2026 · 13 min read

Clinical Research MetaVia's DA-1726 posts -9.1% Phase 1 weight loss and FibroScan signals at EASL Congress 2026 MetaVia's DA-1726 Phase 1 readout at EASL 2026 showed -9.1% body weight at Day 54 and directional li... May 28, 2026 · 11 min read

Regulatory Alabama medical board bans research-grade peptide prescribing, closes consent-form workaround Alabama's medical board on May 26 prohibited physicians from prescribing, compounding, or administer... May 27, 2026 · 12 min read

Clinical Research Lilly's SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN: weight-loss maintenance with lower-dose Zepbound or oral Foundayo Two Lilly Phase 3 trials show people can hold weight loss with lower-dose Zepbound or daily oral Fou... May 26, 2026 · 11 min read

Regulation Oral semaglutide (Wegovy pill) gets EU CHMP backing: what it means for GLP-1 access EU regulators recommended a once-daily 25 mg oral semaglutide tablet for obesity. Here’s what the CH... May 25, 2026 · 10 min read

Regulation FDA restores non-injectable GHK-Cu to 503A Category 1 — what it means for peptide compounding FDA restored non-injectable GHK-Cu to Category 1 of its 503A bulks list on May 14, reversing an Apri... May 23, 2026 · 10 min read

Research NIH locates semaglutide's brain handle: cAMP in area postrema neurons, and a PDE4 inhibitor that sustains it A Nature Metabolism paper out today identifies cAMP signaling in area postrema neurons as the cellul... May 22, 2026 · 10 min read

Clinical Trials Retatrutide hits 28.3% weight loss in TRIUMPH-1: Lilly's triple agonist clears its Phase 3 obesity trial Lilly's triple-agonist retatrutide produced 28.3% mean weight loss at 80 weeks in TRIUMPH-1, the hig... May 21, 2026 · 11 min read

Industry Regeneron bets $125M upfront on Parabilis Helicons: antibody-peptide conjugates step out of the shadows Regeneron's $125M upfront plus $2.2B milestone deal with Parabilis bets antibody-Helicon conjugates ... May 20, 2026 · 14 min read

Regulation FDA warning letter targets retatrutide and tirzepatide ‘research peptides’: what it means for buyers and clinics The FDA’s March 31, 2026 warning letter to Gram Peptides spotlights how ‘research use only’ peptide ... May 19, 2026 · 9 min read

Peptide Research Peptideins: Nature's New Category of Human Molecule Adds 1,785 Entries to the Proteome Nature, May 6: the TransCODE consortium formally names 1,785 microproteins 'peptideins' and adds the... May 18, 2026 · 13 min read

Oncology Peptides BLMP6: UTHealth's Fibulin-4-Targeting Peptide for Metastatic Breast Cancer The Kolonin lab at UTHealth Houston identified BLMP6, a peptide that targets fibulin-4 on invasive b... May 17, 2026 · 11 min read

Neuroscience & GLP-1 Orforglipron Reaches the Central Amygdala: How Oral GLP-1s Turn Down the Dopamine Reward Circuit A new Nature paper from Ali Guler's UVA lab maps how oral GLP-1 drugs like orforglipron reach the ce... May 16, 2026 · 12 min read

Regulation FDA’s July 2026 Peptide Compounding Meeting: What PCAC Could Change for BPC-157, TB-500, Semax, and More FDA will hold a July 23–24, 2026 PCAC meeting on seven peptide bulk substances. Here’s what it means... May 15, 2026 · 10 min read

Drug Discovery & Platforms Suga Lab's RaPID-ExCells Finds HL4, a Macrocyclic Insulin Receptor Agonist Hiroaki Suga's lab at Tokyo published a cell-based mRNA display platform that found HL4, a cyclic pe... May 13, 2026 · 13 min read

Mechanism & Neuroscience GEP-44: What the Syracuse Triple-Agonist Peptide Actually Is, and What the Press Got Wrong Syracuse's GEP-44 is a chimeric GLP-1/Y1/Y2 peptide with strong rodent and shrew data but no human t... May 12, 2026 · 12 min read

Regulatory & Industry Entera Submits Phase 3 Protocol for EB613, the First Oral Anabolic Bone Tablet Entera says EB613, an oral PTH 1-34 tablet, has a Phase 3 protocol at the FDA with feedback expected... May 11, 2026 · 11 min read

Mechanism & Neuroscience GLP-1s, Dopamine, and Falling Out of Love: What the Neuroscience Actually Says GLP-1 receptors sit in the same brain circuits that build romantic bonds. The mechanism users report... May 10, 2026 · 13 min read

Regulatory Ozempic (Semaglutide) Tablets: What the FDA Label Actually Says (Dosing, Switching, Warnings) Ozempic tablets are here. We break down the FDA label: strengths, the 30-day start dose (not for gly... May 10, 2026 · 9 min read

Clinical Trials & Drug Development Avexitide expanded access opens: a GLP-1 receptor antagonist heads to its Phase 3 readout Amylyx opens U.S. expanded access for up to 250 PBH patients on avexitide, the first-in-class GLP-1 ... May 9, 2026 · 10 min read

Regulation & Policy FDA's second PCAC peptide review: the 5 substances heading to a Feb 2027 meeting FDA confirms a second PCAC meeting before end of February 2027 will review LL-37, injectable GHK-Cu,... May 8, 2026 · 11 min read

Regulation & Market Ozempic-branded oral semaglutide hits US pharmacies with primary + secondary CV indication Novo Nordisk's oral semaglutide launches as Ozempic tablets on May 4 with a primary + secondary CV p... May 7, 2026 · 10 min read

Clinical evidence Semaglutide beats dulaglutide on MACE in 75,243-patient Medicare comparison A 75,243-patient Medicare propensity-matched study finds once-weekly semaglutide cut three-point MAC... May 6, 2026 · 9 min read

FDA regulation FDA proposes excluding semaglutide and tirzepatide from the 503B bulks list FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, setting a... May 5, 2026 · 10 min read

regulation-policy FDA's April 7 Warning Letter Batch: How the Bacteriostatic-Water Trigger Is Closing the 'Research Peptides' Lane FDA's April 7 batch of seven warning letters uses bacteriostatic-water pairing to overcome 'research... May 4, 2026 · 10 min read

Regulation FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list—tight... May 3, 2026 · 10 min read

FDA & Policy FDA sets July 2026 PCAC review for key compounding peptides (BPC-157, MOTs-C, Semax) FDA’s July 23–24, 2026 PCAC agenda puts seven peptides (BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, E... May 2, 2026 · 9 min read

cardiovascular GLP-1 Receptor Agonists in Type 1 Diabetes: What the New Cardiorenal Evidence Means A 174,678-patient Hopkins target trial emulation found 15% lower MACE and 19% lower ESKD risk with G... May 1, 2026 · 11 min read

regulation-policy Pop Peptides and the Evidence Gap: What Knoepfler's STAT Essay Gets Right About BPC-157 and GHK-Cu A UC Davis scientist's STAT essay says Kennedy's peptide reversal runs ahead of trial data. What's a... Apr 30, 2026 · 11 min read

Regulation State of Peptides 2026: What the GLP-1 Pipeline and FDA Policy Signals Mean Now FormBlends’ 2026 State of Peptides report highlights how FDA compounding policy and the GLP-1 pipeli... Apr 29, 2026 · 10 min read

regulation-policy FDA Sets July 23-24 PCAC Vote on Seven Peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon FDA's July 23-24 PCAC will vote on seven peptides for the 503A Bulks List. Two dockets are open. Jul... Apr 28, 2026 · 9 min read

weight-loss-metabolic Tirzepatide Linked to Fewer Cardiac Events After PCI and TAVR: Three Propensity-Matched Studies at SCAI 2026 and AACE 2026 Three propensity-matched studies presented April 23-24 link tirzepatide to fewer deaths and major ca... Apr 27, 2026 · 9 min read

Research Tirzepatide vs Semaglutide Cost-Effectiveness: SURMOUNT-5 Lifetime Model Shows $41,688 Per-Patient Savings A new lifetime simulation built on SURMOUNT-5 data finds tirzepatide saves $41,688 per patient and a... Apr 26, 2026 · 8 min read

Regulation & Policy FDA Opens Docket FDA-2025-N-6895 for July 2026 PCAC Peptide Review FDA opened docket FDA-2025-N-6895 ahead of the July 23–24, 2026 PCAC meeting on seven peptides. What... Apr 25, 2026 · 5 min read

Regulation & Policy FDA Import Alert 66-80: GLP-1 and Peptide Bulk API Now Detained at the Border FDA has updated Import Alert 66-80 to authorize Detention Without Physical Examination for bulk GLP-... Apr 24, 2026 · 12 min read

Research & Discovery SAB-142 Phase 1 Data: C-Peptide Preservation in Established Type 1 Diabetes At IDS 2026 on April 22, SAB Biotherapeutics reported that all four adults with established Type 1 D... Apr 23, 2026 · 10 min read

Regulation & Policy FDA’s Peptide ‘Rally’ Update: Supply Chain and Enforcement Are the Real Bottlenecks A fresh follow-up from the FDA Law Blog (Apr 22, 2026) argues the biggest barrier to “peptides being... Apr 22, 2026 · 11 min read

Regulation & Policy FDA’s ‘Peptide Rally’: What Changed — and What Hasn’t (Yet) A new analysis from the FDA Law Blog explains why the FDA’s recent ‘Category 2 removal’ headlines do... Apr 21, 2026 · 9 min read

Regulation & Policy How to Submit Public Comments on FDA Peptide Compounding (Docket FDA-2025-N-6895) The FDA has opened docket FDA-2025-N-6895 for public comments on seven peptides — including BPC-157,... Apr 20, 2026 · 8 min read

Regulation & Policy FDA Sets July 2026 PCAC Hearing for BPC-157, TB-500, MOTS-C, Semax, and More The FDA has published the agenda for its July 23–24, 2026 Pharmacy Compounding Advisory Committee (P... Apr 18, 2026 · 10 min read

Research & Discovery BRP: Stanford's AI-Discovered Peptide That Could Replace Ozempic Stanford researchers used an AI algorithm called Peptide Predictor to scan 20,000 human genes and di... Apr 18, 2026 · 12 min read

Regulation & Policy FDA Peptide Reclassification 2026: Which 12 Peptides Are Being Restored Under RFK Jr. In April 2026, the FDA announced it would remove 12 peptides from its Category 2 list, reversing a s... Apr 17, 2026 · 12 min read

All News & Research Stay Updated
About

Search peptides

Today's News FDA PCAC July 2026: What the BPC-157 peptide compounding review really means Jun 2, 2026

View all articles 45 new

Home / Categories / Antiviral

Antiviral

Peptides that inhibit viral entry, replication, or immune evasion.

0 peptides in this category

Related Categories

Growth Hormone Secretagogues Healing & Recovery Sexual Health Cognitive & Nootropic

PeptideKnow

peptideknow.com

An independent peptide reference database for the scientific and research community. All information is for educational purposes only.

Browse

All Peptides
Categories
News & Research
Search
About

Guides

Beginner's Guide
Stacking Guide
Routes of Administration
Reconstitution
How Peptides Are Made
Peptides vs SARMs

Tools & Resources

Reconstitution Calculator
Healing & Recovery
GH Secretagogues

Official Sources

NIH·NLM PubMed
NIH ClinicalTrials.gov
U.S. FDA FDA.gov
NCBI NCBI
WHO World Health Org.
DOI doi.org

Popular Peptides

BPC-157
Semaglutide
TB-500
Epithalon
GHK-Cu

Trusted Partners

USA Peptides

© 2026 PeptideKnow. All rights reserved. This website is for informational and educational purposes only. It does not provide medical advice. Consult a qualified healthcare professional before making any health decisions.

Sitemap RSS Feed